BioAge Labs, Inc.(BIOA)Earnings, Financials & Key RatiosBioAge Labs, Inc. (BIOA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company holds a significant $241.8 million cash reserve to fund operations, the lack of commercial revenue and the $355.7 million accumulated deficit suggest high execution risk for long-term investors.
BioAge Labs, Inc. (BIOA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BioAge Labs, Inc. (BIOA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.52vs $0.64+18.7% | $3Mvs $1M+155.9% |
| Q2 2026 | May 5, 2026 | $0.52vs $0.64+18.7% | $3Mvs $1M+155.9% |
| Q2 2026 | Mar 24, 2026 | $0.72vs $0.83+13.3% | $3Mvs $1M+119.9% |
| Q4 2025 | Nov 6, 2025 | $0.56vs $0.67+16.4% | $2Mvs $1M+80.2% |
Recent stock market news and headlines for BioAge Labs, Inc. (BIOA)
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif.
Key metrics vs top competitors for BioAge Labs, Inc. (BIOA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.40 | $918.65M | -10.89 | — | -896.11% | -27.09% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $114.46 | $7.84B | -36.80 | 45.83% | -93.84% | -204.35% | — | |
| $6.39 | $377.7M | -1.71 | 8.72% | -109.99% | -61.41% | — |
BioAge Labs, Inc. (BIOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BioAge Labs, Inc. (BIOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 12, 2026·SEC
May 8, 2026·SEC
Mar 24, 2026·SEC
Get notified when BIOA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioAge Labs, Inc. (BIOA) stock FAQ — growth, dividends, profitability & financials explained
BioAge Labs, Inc. (BIOA) reported $10.3M in revenue for fiscal year 2025.
BioAge Labs, Inc. (BIOA) reported a net loss of $89.9M for fiscal year 2025.
BioAge Labs, Inc. (BIOA) has a return on equity (ROE) of -27.1%. Negative ROE indicates the company is unprofitable.
BioAge Labs, Inc. (BIOA) had negative free cash flow of $88.6M in fiscal year 2025, likely due to heavy capital investments.
